rss
Br J Ophthalmol 88:450-454 doi:10.1136/bjo.2003.035279
  • Value-based ophthalmology

Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants

Table 4

Cost utility output for each screening age scenario both including and excluding savings from reduced photodynamic therapy (PDT) costs

Screening age Excluding PDT savings Including PDT savings
Cost per QALY Cost per QALY
£ A$ £ A$
55+ 23 704 49 092 19 963 41 344
65+ 22 722 47 058 18 948 39 242
70+ 22 937 47 502 19 087 39 528
75+ 23 422 48 506 20 030 41 482

This Article

  1. Abstract
  2. Full text
  3. PDF

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.